Aberrant LYZ expression in tumor cells serves as the potential biomarker and target for HCC and promotes tumor progression via csGRP78
Proceedings of the National Academy of Sciences · 18.07.2023 · 120 (29)
DOI: 10.1073/pnas.2215744120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 10.07.2023. Verfasst von Zhiwen Gu und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics,…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key RD Program of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) takes the predominant malignancy of hepatocytes with bleak outcomes owing to high heterogeneity among patients. Personalized treatments based on molecular profiles will better improve patients’ prognosis. Lysozyme (LYZ), a secretory protein with antibacterial function generally expressed in monocytes/macrophages, has been observed for the prognostic implications in different types of tumors. However, studies about the explicit applicative scenarios and mechanisms for tumor progression are still quite limited, especially for HCC. Here, based on the proteomic molecular classification data of early-stage HCC, we revealed that the LYZ level was elevated significantly in the most malignant HCC subtype and could serve as an independent prognostic predictor for HCC patients. Molecular profiles of LYZ-high HCCs were typical of those for the most malignant HCC subtype, with impaired metabolism, along with promoted proliferation and metastasis characteristics. Further studies demonstrated that LYZ tended to be aberrantly expressed in poorly differentiated HCC cells, which was regulated by STAT3 activation. LYZ promoted HCC proliferation and migration in both autocrine and paracrine manners independent of the muramidase activity through the activation of downstream protumoral signaling pathways via cell surface GRP78. Subcutaneous and orthotopic xenograft tumor models indicated that targeting LYZ inhibited HCC growth markedly in NOD/SCID mice. These results propose LYZ as a prognostic biomarker and therapeutic target for the subclass of HCC with an aggressive phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China.
- Research Unit of Proteomics-driven Cancer Precision Medicine, Chinese Academy of Medical Sciences, Beijing 102206, China.
- Faculty of Environment and Life, Beijing University of Technology, Beijing 100124, China.
- Department of Pathology, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China.
ORCID-Profile: Zhiwen Gu, Songpeng Yang, Cheng Chang, Fuchu He, Aihua Sun
Förderung
- National Key RD Program of China
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
- China Postdoctoral Science Foundation
- National Natural Science Fundation of China
- Open Project Program of the State Key Laboratory of Proteomics
Zitieren
APA
Gu, Z., Wang, L., Dong, Q., Xu, K., Ye, J., Shao, X., Yang, S., Lu, C., Chang, C., Hou, Y., Zhai, Y., Wang, X., He, F., & Sun, A. (2023). Aberrant LYZ expression in tumor cells serves as the potential biomarker and target for HCC and promotes tumor progression via csGRP78. Proceedings of the National Academy of Sciences, 120(29). https://doi.org/10.1073/pnas.2215744120
Vancouver
Gu Z, Wang L, Dong Q, Xu K, Ye J, Shao X, et al. Aberrant LYZ expression in tumor cells serves as the potential biomarker and target for HCC and promotes tumor progression via csGRP78. Proceedings of the National Academy of Sciences. 2023;120(29). doi:10.1073/pnas.2215744120
BibTeX
@article{Gu2023,
author = {Gu, Zhiwen and Wang, Lei and Dong, Qian and Xu, Kaikun and Ye, Jingnan and Shao, Xianfeng and Yang, Songpeng and Lu, Cuixiu and Chang, Cheng and Hou, Yushan and Zhai, Yuanjun and Wang, Xinxin and He, Fuchu and Sun, Aihua},
title = {Aberrant LYZ expression in tumor cells serves as the potential biomarker and target for HCC and promotes tumor progression via csGRP78},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
volume = {120},
number = {29},
doi = {10.1073/pnas.2215744120}
}
EUVIMED